Related Experiment Video
Updated: May 19, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Pathology of gastrointestinal stromal tumors
Wai Chin Foo1, Bernadette Liegl-Atzwanger, Alexander J Lazar
1Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract:
Gastrointestinal stromal tumor (GIST) is a well recognized and relatively well understood soft tissue tumor. Early events in GIST development are activating mutations in KIT or PDGFRA, which occur in most GISTs and encode for mutated tyrosine receptor kinases that are therapeutic targets for tyrosine kinase inhibitors, including imatinib and sunitinib. A small minority of GISTs possessing neither KIT nor PDGFRA mutations may have germline mutations in SDH, suggesting a potential role of SDH in the pathogenesis. Immunohistochemical detection of KIT, and more recently DOG1, has proven to be reliable and useful in the diagnosis of GISTs. Because current and future therapies depend on pathologists, it is important that they recognize KIT-negative GISTs, GISTs in specific clinical contexts, GISTs with unusual morphology, and GISTs after treatment. This review focuses on recent developments in the understanding of the biology, immunohistochemical diagnosis, the role of molecular analysis, and risk assessment of GISTs.
Insights
Gastrointestinal stromal tumors (GISTs) are driven by KIT or PDGFRA mutations, targeted by kinase inhibitors. Understanding GIST biology, diagnosis, and molecular analysis is crucial for effective patient treatment.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Gastrointestinal stromal tumors (GISTs) are well-characterized soft tissue neoplasms.
- Activating mutations in KIT or PDGFRA are early events in most GISTs, encoding mutated tyrosine receptor kinases.
- A subset of GISTs without KIT/PDGFRA mutations may involve germline mutations in Succinate Dehydrogenase (SDH).
Purpose of the Study:
- To review recent advancements in GIST biology.
- To discuss immunohistochemical diagnostic markers like KIT and DOG1.
- To highlight the importance of molecular analysis and risk stratification in GIST management.
Main Methods:
- Review of current literature on GIST pathogenesis, diagnosis, and therapy.
- Focus on immunohistochemical techniques and molecular genetic analysis.
- Discussion of clinical contexts, morphology, and post-treatment GIST assessment.
Main Results:
- KIT and PDGFRA mutations are key drivers of GIST development and therapeutic targets.
- Immunohistochemistry for KIT and DOG1 are reliable diagnostic tools.
- SDH mutations play a role in a minority of GIST cases, indicating diverse pathogenic mechanisms.
Conclusions:
- Accurate diagnosis and understanding of GIST biology are essential for effective treatment with tyrosine kinase inhibitors.
- Pathologists must recognize KIT-negative GISTs, unusual presentations, and post-treatment changes.
- Molecular analysis and risk assessment are integral to personalized GIST therapy.
